Literature DB >> 16779852

Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis.

Dena Nazer1, Ibrahim Abdulhamid, Ronald Thomas, Sara Pendleton.   

Abstract

To compare the effectiveness of home versus hospital intravenous (IV) antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis (CF). A retrospective chart review was performed of 143 encounters for pulmonary exacerbations in 50 patients with CF. All encounters were categorized into two groups based on location of completion of antibiotic therapy: hospital group completed treatment in hospital (n = 64), home group completed treatment at home (n = 79). Percent change was calculated for forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV1), forced expiratory flow rate between 25 percent and 75 percent of vital capacity (FEF(25-75%)), maximum forced expiratory flow (FEF(max)), oxygen saturation (O2 SAT), and weight. Means of percent change (PC) from the beginning to the end of IV antibiotic treatment in outcome variables were compared. Total duration of treatment was compared between the two groups. The two groups had no significant differences at baseline in all outcome variables. Treatment of exacerbations in both groups resulted in significant improvement of lung function, O2 SATS, and weight (P <or= 0.001). The percent change in FEV1 was greater in hospital group versus home group (P = 0.04). The duration of treatment was significantly shorter in the hospital group (P = 0.001). Home and hospital IV antibiotic therapy resulted in significant improvement in lung function and weight. Hospital therapy, however, resulted in significantly greater improvement in FEV-1 and required less duration of treatment as compared to home treatment in children with CF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779852     DOI: 10.1002/ppul.20433

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  15 in total

1.  Home intravenous therapy: Accessibility for Canadian children and youth.

Authors:  Dl Moore; R Bortolussi
Journal:  Paediatr Child Health       Date:  2011-02       Impact factor: 2.253

2.  Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Authors:  J Michael Collaco; Deanna M Green; Garry R Cutting; Kathleen M Naughton; Peter J Mogayzel
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

3.  Effects of lung transplantation on inpatient end of life care in cystic fibrosis.

Authors:  Elisabeth P Dellon; Margaret W Leigh; James R Yankaskas; Terry L Noah
Journal:  J Cyst Fibros       Date:  2007-05-03       Impact factor: 5.482

4.  Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

Authors:  D R VanDevanter; P A Flume; N Morris; M W Konstan
Journal:  J Cyst Fibros       Date:  2016-04-29       Impact factor: 5.482

5.  Serum insulin-like growth factor-1 (IGF-1) during CF pulmonary exacerbation: trends and biomarker correlations.

Authors:  A H Gifford; A B Nymon; A Ashare
Journal:  Pediatr Pulmonol       Date:  2013-06-18

6.  Domiciliary administration of intravenous albumin in congenital nephrotic syndrome.

Authors:  Ben Christopher Reynolds; Charles William Pickles; Heather Joan Lambert; Milos Ognjanovic; Jean Crosier; Sally Ann Johnson; Yincent Tse
Journal:  Pediatr Nephrol       Date:  2015-08-07       Impact factor: 3.714

7.  Outcomes and Safety of Outpatient Parenteral Antimicrobial Therapy in Select Children with Cystic Fibrosis.

Authors:  Gulnur Com; Amit Agarwal; Shasha Bai; Zhuopei Hu; Grace Goode; Hollyn McCarty; Ariel Berlinski
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-12-11       Impact factor: 1.349

8.  Home intravenous antibiotic therapy in children with cystic fibrosis: clinical outcome, quality of life and economic benefit.

Authors:  E A Chrysochoou; E Hatziagorou; F Kirvassilis; J Tsanakas
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

9.  Hospital versus home treatment of respiratory exacerbations in cystic fibrosis.

Authors:  Moran Lavie; Daphna Vilozni; Gil Sokol; Raz Somech; Amir Szeinberg; Ori Efrati
Journal:  Med Sci Monit       Date:  2011-12

10.  Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?

Authors:  Iara Maria Sequeiros; Nabil A Jarad
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.